This trial is evaluating whether LM-302 will improve 14 primary outcomes, 13 secondary outcomes, and 1 other outcome in patients with Solid Tumors, Advanced Solid Tumors. Measurement will happen over the course of Cycle 1 of each cohort. Duration of one cycle is 21 days.
This trial requires 42 total participants across 6 different treatment groups
This trial involves 6 different treatments. LM-302 is the primary treatment being studied. Participants will be divided into 6 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"In summary, LM-302 is a new oncology drug candidate that selectively targets and destroys tumor cells. As a small-molecule, it possesses interesting anti-proliferative and anti-metastatic properties, which could increase clinical therapeutic benefit of LM-302 as a novel chemotherapy agent for multiple cancers." - Anonymous Online Contributor
"Results of this first-in-human assessment of LM-302 show that lm-302 has measurable antimitotic and proapoptotic properties, and demonstrates activity against advanced cancer in patients with solid tumors. The findings provide proof-of-concept that in conjunction with our targeted and personalized tumor immunotherapy strategies, targeting cell division through antimitotic or apoptotic mechanisms will be highly effective in treating advanced cancer." - Anonymous Online Contributor
"Solid tumors are often treated using medical imaging or ultrasound for visualization of the tumor in order to gain access. This technique provides treatment options for patients with tumors located in remote sites, while also allowing for a more precise targeting of the tumor and the surrounding tissue. There are significant disadvantages, including the risks of tumor manipulation, cancer cell dissemination and toxicity if the imaging or ultrasound technique is used. In many cases, patients become resistant to the treatment because of the low concentration and penetration of the chemotherapy drugs inside the growing solid tumor. Because imaging or ultrasound techniques cannot provide the desired levels of drug penetration, new ways of target solid lesions and tumours are desired, i.e. targeted therapy to enhance drug distribution inside the cancer." - Anonymous Online Contributor
"In the United States, treatments typically involve a combination of surgery, radiation, and chemotherapy, in addition to targeted medications. Survival rates for locally advanced solid tumors are improving, most likely because of advances in surgery. Survival rates for metastatic patients is generally poor: in 2004, only 5% had a median survival of more than 5 years." - Anonymous Online Contributor
"Cancer treatment can result in cure of a subset of patients with a good quality of life. However, a large proportion of patients will still have a low quality of life and a limited number of anticancer drugs that can offer significant results." - Anonymous Online Contributor
"Solid tumors are tumors that do not have a liquid or solid component in them. They may be metastatic or non-metastatic. They are differentiated or undifferentiated. Usually they are benign or malignant tumors. Advanced solid tumors are cancers that have spread to other parts of the body. A solid tumor that has not spread is called a primary or isolated solid tumor. They are differentiated or undifferentiated. Solid tumors may show tumors with different types of tissue differentiation, or differentiation. They may be benign or malignant. Usually they are benign or malignant tumors." - Anonymous Online Contributor
"The number of people with cancers of the colon, lung or stomach grew by more than 40% from 1980 to 2010. The number of people with solid tumors, lung cancers, and advanced solid tumors grew by more than 70% from 1980 to 2010. The number of people diagnosed with advanced solid tumors continued to decline from 2010 to 2015." - Anonymous Online Contributor
"Sudden onset of a new persistent, nonreducible mass in the lower abdominal or pelvic region are common signs of advanced solid tumors. Painful masses and abdominal mass, pelvic pain, constipation and weakness may also be manifested." - Anonymous Online Contributor
"Recent findings identified important clinical characteristics that may allow us to assess the propensity for clinical trial candidates to enroll in trial. Patients who presented clinically for treatment other than chemotherapy had markedly different outcomes in that trial." - Anonymous Online Contributor
"Results from a recent clinical trial of this study illustrate that the novel anti-tumor efficacy of LM-302, which is independent of the AKT pathway, can be explained by the potentiation of the autophagic cell death mediated by activation of the p70S6K/RPS6 pathway. Therefore, combination of the anti-tumor activity mediated by cIAP2 inhibition with the autophagy augmentation may provide an effective adjuvant therapy for patients with solid tumors." - Anonymous Online Contributor
"Solid cancers that affect people less than 55 and over age 75 account for 10% and 29% of all new cases and deaths from solid cancers in the United States, respectively. People over the age of 75 are less likely than those under the age of 55 to receive medical attention for symptoms indicating cancer. These factors need to be taken into account for a full understanding of the impact of solid cancers on society." - Anonymous Online Contributor
"Lm-302 is in phase IIa clinical trials for solid tumors. Lm-302 has a dual mechanism of action: an inhibitor of aldehyde dehydrogenase 1 and a pro-adrenaline receptor agonist, thus it may be able to selectively kill tumor cells by inhibiting the metabolism of a variety of pro-malignant and pro-inflammatory compounds." - Anonymous Online Contributor